Philip J. Gold, MD
Seattle, WA 98104
Are you covered?
Check to see if your insurance is covered by this provider.
About Philip J. Gold
Dr. Gold is a multiple time recipient of the Seattle Top Doctor Award and most recently received the 2023 Seattle Magazine Top Doc Award. Dr. Gold is Director of Clinical Research and the Program Leader for the Gastrointestinal (GI) Oncology Program at the Swedish Cancer Institute in Seattle, Washington. In 1991, Dr. Gold obtained his degree in medicine with a distinction in research at the University of Miami School of Medicine in Florida. He then completed an internal medicine internship and residency at the University of Washington. Dr. Gold received the Amgen Oncology Fellowship Award while he was training in medical oncology at the University of Washington School of Medicine and the Fred Hutchinson Cancer Research Center.
Presently, he is board certified in medical oncology. Dr. Gold’s clinical investigations on GI tumors, and particularly colorectal cancer treatment, can be found in peer-reviewed publications like the Journal of Clinical Oncology, Seminars in Oncology, and Cancer Investigation. Furthermore, he currently serves as a member of the NCI Colon Task Force, and the Southwest Oncology Group, where he serves as the subcommittee co-chair for colon cancer.
In his free time, Dr. Gold enjoys photography and spending time with his wife and three sons.
University of Washington, WA - Medical Oncology; Fred Hutchinson Cancer Research Center, WAResidency
University of Washington School of MedicineMedical School
University of Miami Leonard M. Miller School of Medicine
- American Board of Internal Medicine, Medical Oncology
- Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors
- a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma.
- a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma
- A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.
- Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415).
- Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336).
- Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
- Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
- UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
- Phase II trial of paclitaxel, 13-cis retinoic acid and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer
- Long-term survival after continuous infusion interleukin-2.
- Metastatic renal cell carcinoma: long-term survival after therapy with high-dose continuous-infusion interleukin-2.
- Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
- Paraneoplastic manifestations of renal cell carcinoma.
- Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer.
- First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.
- Phase I trial of irinotecan and epirubicin in patients with advanced solid tumors
- Pharmacokinetic Analysis of Irinotecan Plus Bevacizumab in Patients with Advanced Solid Tumors
- Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
- A Phase II study of Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in the Treatment of Metastatic Colorectal Cancer
- Phase II Trial of Irinotecan in Patients With Metastatic Epithelial Ovarian Cancer or Peritoneal Cancer
- Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
- Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.
- Clinical Trials are Key to new cancer treatments
1221 Madison Street, Suite 200
Seattle, WA 98104
Swedish Cherry Hill
Swedish First Hill
At Swedish, we're dedicated to providing you quality, personalized health care. We are constantly striving to optimize your experience.
As part of ensuring you have a positive experience with Swedish, our online provider directory includes ratings and patient comments for select providers. More about our survey.
Dr. Gold and his staff are exceptional.
Dr gold is wonderful and his staff even better
The reception was warm and the condition was explained clearly. I was very satisfied with him after several contacts
Above and beyond excellent service
Dr Gold and his staff are wonderful and very kind.
I have been seeing Dr. Gold for 10 years and have always appreciated his attention to detail and prompt action. He has involved other Swedish specialist care providers when needed and I have been very satisfied with his recommendations.
I have never had a bad experience, they're so good care including receptionist as well.
Dr. Gold is always reassuring with the needed treatment. He explains the test results and what future appointments will involve. I truly appreciate his expertise on colon cancer.
Dr Gold and all his staff provide excellent care and support.
Everyone at the clinic, from the receptionists to the physician to the lab personnel, was helpful, courteous and professional.
Dr Gold was clear forthcoming helpful
Thank you so much for taking care of me, the staff and the doctor and anyone in my care team who provided me a care during my visit.
Dr Gold is excellent very nice take care Good on his clients thank you very much
Very compassionate; good explainer
My core care team is excellent - on some of the other teams (i.e. Chemo) scheduling & communication need improvement.
Experience is always great
Dr always forthcoming with the currently important information.
I receive excellent care from Dr. Gold. He is fully familiar with my health history and takes care to recommend necessary follow-on treatments. I have the utmost confidence in him.
Wonderful care. He really is compassionate and makes me feel loved
Dr Gold is an outstanding physician with a great understanding and empathy
Experience has been very good and timely
I drive 2 hours to see this practice so ...yep I highly recommend
Dr. Gold always made me feel that my health is very important to him. He is caring, meticulous, makes sure that if I need an appointment with another specialist I will get it fast. He is the best!
Dr Gold and his staff are awesome! They are all so caring and kind.
I feel honored to have been a part of this clinic. Dr. Gold is the best. I thank all of you.
- Aids Related Malignancies
- Anal Cancer
- Anaplastic Meningioma
- Anorectal Cancer
- Appendiceal Cancer
- Atypical Meningioma
- Biliary Tract Cancer
- Bladder Cancer Genomics
- Brain Cancer Genomics
- Breast Cancer
- Breast Cancer Chemotherapy
- Breast Cancer Genomics
- Cancer Chemotherapy
- Cancer During Pregnancy
- Cancer Genomics
- Cancer Pain
- Cancer Rehabilitation
- Cancer Related Anxiety Disorder
- Cancer Related Bereavement Disorder
- Cancer Related Depression
- Cancer Related Fatigue
- Cancer Related Psychiatric Disorder
- Cancer Related Stress Disorder
- Cancer Risk Assessment
- Cancer Survivor
- Carcinoid Of Stomach
- Carcinoid Tumor
- Carcinoid Tumor Of Pancreas
- Carcinoma Of Unknown Primary
- Cervical Cancer Genomics
- Clear Cell Meningioma
- Clinical Trials
- Colon Cancer
- Colon Cancer Chemotherapy
- Colon Cancer Genomics
- Colorectal Cancer
- Cystadenoma Of Pancreas
- Egfr Mutation
- Egfr Translocation
- Endocrine Complications Of Cancer Therapy
- Endometrial Cancer Genomics
- Epithelioid Hemangioendothelioma
- Epithelioid Malignant Peripheral Nerve Sheath Tumor
- Fibrous Meningioma
- Gallbladder Cancer
- Gallbladder Cancer Genomics
- Gastrin Secreting Tumor Of Pancreas
- Gastroesophageal Junction Cancer
- Gastrointestinal (Gi) Cancer
- Gastrointestinal (Gi) Cancer Genomics
- Gastrointestinal Stromal Tumors (Gist)
- Genitourinary Cancer Genomics
- Giant Cell Tumor Of The Bone
- Gynecologic Cancer Genomics
- Head And Neck Cancer
- Head And Neck Cancer Genomics
- Histiocytic Sarcoma
- Immature Teratoma
- Islet Cell Tumor
- Leukemia Genomics
- Liver Cancer Genomics
- Liver Mass
- Lung Cancer Genomics
- Lymphedema Therapy
- Lymphoma Genomics
- Lynch Syndrome
- Malignant Neoplasm Of Liver
- Malignant Neoplasm Of Pancreatic Duct
- Malignant Rectal Neoplasm
- Malignant Tumor Of Extrahepatic Bile Duct
- Melanoma Genomics
- Melanoma Of The Rectum
- Melanoma On Foot
- Melanoma On Leg
- Melanoma On Toe
- Melanoma On Trunk
- Melanoma Surgery
- Melanotic Schwannoma
- Meningeal Melanoma
- Metastatic Colon Cancer
- Metastatic Liver Cancer
- Mucosal Melanoma
- Musculoskeletal Tumor
- Myeloproliferative Diseases
- Neuroendocrine Tumors
- Non Germinomatous Germ Cell Tumor
- Non Hodgkin Lymphoma
- Oral Complications Of Cancer
- Oral Lesions
- Pancreas Cancer
- Pancreas Head Cancer
- Pancreas Tail Cancer
- Pancreatic Cancer Genomics
- Pancreatic Mass
- Personal History Of Malignant Neoplasm Of Liver
- Plasma Cell Dyscrasia
- Prostate Cancer Genomics
- Pseudomyxoma Peritonei
- Pulmonary Metastases
- Rectal Cancer Genomics
- Recurrent Colorectal Cancer
- Renal Cancer Genomics
- Retroperitoneal Mass
- Sarcoma Genomics
- Side Effects Of Cancer Treatment
- Skin Cancer Genomics
- Small Bowel Cancer
- Squamous Cell Carcinoma Of The Head And Neck
- Squamous Cell Carcinoma Of The Tongue
- Stomach Cancer
- Stomach Cancer Genomics
- Supratentorial Primitive Neuroectodermal Tumor
- Targeted Molecular Therapy
- Teratoma With Malignant Transformation
- Thoracic Cancer
- Thyroid Cancer Genomics
- Tracheal Cancer
- Unknown Primary Cancer
- Vaginal Melanoma